Effect of pioglitazone on endothelial function in impaired glucose tolerance

Diabetes, Obesity and Metabolism

Volumn 12, Issue 8, 2010, Pages 709-715

  Quinn, C E ^a   Lockhart, C J ^a   Hamilton, P K ^a   Loughrey, C M ^b   McVeigh, G E ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Cardiovascular disease; Insulin resistance; Microvascular disease; Randomized trial; Thiazolidinediones

Indexed keywords

ADIPONECTIN; INSULIN; PIOGLITAZONE; PLACEBO;

ADULT; ARTICLE; BRACHIAL ARTERY; CALCULATION; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM; FEMALE; HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MOLECULAR WEIGHT; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SHEAR STRESS; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VASCULARIZATION; VASODILATATION;

EID: 77958100255     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01224.x     Document Type: Article

References (39)

1. Santaguida PL, Balion C, Hunt D et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess (Summ) 2005; 128: 1-11.
2. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall Study. Lancet 1980; 1: 1373-1376.
3. Qiao Q, Jousilahti P, Eriksson J, Tuomilehto J. Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. Diabetes Care 2003; 26: 2910-2914.
4. Quyyumi AA. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 1998; 105: 32S-39S.
5. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-2678.
6. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003; 108: 2093-2098.
7. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flowmediated dilation predicts incident cardiovascular events in older adults: the cardiovascular health study. Circulation 2007; 115: 2390-2397.
8. Anderson TJ. Prognostic significance of brachial flow-mediated vasodilation. Circulation 2007; 115: 2373-2375.
9. Koller A, Kaley G. Endothelial regulation of wall shear stress and blood flow in skeletal muscle microcirculation. Am J Physiol 1991; 260: H862-H868.
10. Silber HA, Bluemke DA, Ouyang P, Du YP, Post WS, Lima J. The relationship between vascular wall shear stress and flow-mediated dilation: endothelial function assessed by phase-contrast magnetic resonance angiography. J Am Coll Cardiol 2001; 38: 1859-1865.
11. Mitchell GF, Parise H, Vita JA et al. Local shear stress and brachial artery flow-mediated dilation: the Framingham heart study. Hypertension 2004; 44: 134-139.
12. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8: 316-320.
13. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treatedwith troglitazone. N Engl J Med 1994; 331: 1188-1193.
14. Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554.
15. Xiang AH, Peters RK, Kjos SL et al. Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 1986-1991.
16. Choi D, Kim SK, Choi SH et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27: 2654-2660.
17. Nissen SE, Nicholls SJ, Wolsk, K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299: 1561-1573.
18. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferatoractivated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 52-57.
19. Iwaki M, Matsuda M, Maeda N et al. Induction of adiponectin, a fatderived anti-diabetic and anti-atherogenic factor, by nuclear receptors. Diabetes 2003; 52: 1655-1663.
20. Wright SA, O'Prey FM, Rea DJ et al. Microcirculatory haemodynamics and endothelial dysfunction in systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2006; 26: 2281-2287.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
22. Corretti MC, Anderson TJ, Benjamin EJ et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the international brachial artery reactivity task force. J Am Coll Cardiol 2002; 39: 257-265.
23. Su Y, Liu XM, Sun YM et al. The relationship between endothelial dysfunction and oxidative stress in diabetes and prediabetes. Int J Clin Pract 2008; 62: 877-882.
24. Caballero AE, Arora S, Saouaf R et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999; 48: 1856-1862.
25. Cooke JP, Rossitch E Jr, Andon NA, Loscalzo J, Dzau VJ. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J Clin Invest 1991; 88: 1663-1671.
26. McVeigh GE, Brennan GM, Johnston GD et al. Impaired endotheliumdependent and independent vasodilation in patients with type 2 (noninsulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 771-776.
27. Watts GF, O'Brien SF, Silvester W, Millar JA. Impaired endotheliumdependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin Sci (Lond) 1996; 91: 567-573.
28. Tan KC, Xu A, Chow WS et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 2004; 89: 765-769.
29. Ouchi N, Ohishi M, Kihara S et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231-234.
30. Majithiya JB, Paramar AN, Balaraman R. Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc Res 2005; 66: 150-161.
31. Martens FM, Visseren FL, de Koning EJ, Rabelink TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 2005; 46: 773-778.
32. Sourij H, Zweiker R, Wascher TC. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care 2006; 29: 1039-1045.
33. Campia U, Matuskey LA, Panza JA. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endotheliumdependent dilation in non-diabetic patients with major cardiovascular risk factors. Circulation 2006; 113: 867-875.
34. Buchanan TA, Meehan WP, Jeng YY et al. Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest 1995; 96: 354-360.
35. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 1994; 24: 170-175.
36. Standley PR, Zhang F, Ram JL, Zemel MB, Sowers JR. Insulin attenuates vasopressin-induced calcium transients and a voltage-dependent calcium response in rat vascular smooth muscle cells. J Clin Invest 1991; 88: 1230-1236.
37. Hara K, Horikoshi M, Yamauchi T et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006; 29: 1357-1362.
38. Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2006; 65: 722-728.
39. Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-2791.